Get the Stockscreener App
2.26
5.61%
0.12
Pre-market:
2.16
-0.10
-4.42%
Aptevo Therapeutics Inc stock is traded at $2.26, with a volume of 43,757.
It is up +5.61% in the last 24 hours and down -27.10% over the past month.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
See More
Previous Close:
$2.14
Open:
$2.15
24h Volume:
43,757
Relative Volume:
0.02
Market Cap:
$7.29M
Revenue:
$12.99M
Net Income/Loss:
$-23.72M
P/E Ratio:
-0.0232
EPS:
-97.2514
Net Cash Flow:
$-23.28M
1W Performance:
-15.67%
1M Performance:
-27.10%
6M Performance:
-97.17%
1Y Performance:
-99.27%
1-Day Range:
$2.14
$2.26
1-Week Range:
$2.0992
$2.80
52-Week Range:
$2.0992
$381.10
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Name
Aptevo Therapeutics Inc
Sector
Industry
Phone
206-838-0500
Address
2401 4TH AVE., SEATTLE, WA
Compare APVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
2.26 | 7.00M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-05-17 | Resumed | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Stock (APVO) Latest News
Evaluating Aptevo Therapeutics Inc. with trendline analysisReal Time Trade Execution Alert Plan - Newser
Is Aptevo Therapeutics Inc. likely to announce a buybackBest ROI Stocks This Month - sisain.net
Why Aptevo Therapeutics Inc. stock attracts strong analyst attentionWeekly Chart Watchlist with Trade Guidance - Newser
Historical volatility pattern of Aptevo Therapeutics Inc. visualizedRisk-Managed Swing Setup and Signal Analysis - Newser
Using data models to predict Aptevo Therapeutics Inc. stock movementSafe Entry Screening with Data Backed Analysis - Newser
Aptevo Therapeutics and 60 Degrees Pharmaceuticals to be Featured on Bloomberg TV's RedChip Small Stocks, Big Money Show - AInvest
Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Daily Corinthian
Aptevo Therapeutics (APVO) Expected to Announce Quarterly Earnings on Thursday - Defense World
Multi factor analysis applied to Aptevo Therapeutics Inc.Real Chart Based Opportunity Identification - Newser
How volatile is Aptevo Therapeutics Inc. stock compared to the marketDiscover top stock picks for aggressive growth - Jammu Links News
What institutional investors are buying Aptevo Therapeutics Inc. stockMaximize portfolio value with timely trades - Jammu Links News
Is Aptevo Therapeutics Inc. a good long term investmentMaximize portfolio growth with expert advice - Jammu Links News
How does Aptevo Therapeutics Inc. generate profit in a changing economyDiscover undervalued stocks ready to soar - Jammu Links News
How does Aptevo Therapeutics Inc. compare to its industry peersDiscover high-impact stocks for your portfolio - Jammu Links News
Is it the right time to buy Aptevo Therapeutics Inc. stockHigh-octane financial growth - Jammu Links News
How strong is Aptevo Therapeutics Inc. company’s balance sheetBuild a portfolio for long-term financial success - Jammu Links News
Why is Aptevo Therapeutics Inc. stock attracting strong analyst attentionCapitalize on emerging growth stocks - Jammu Links News
Does Aptevo Therapeutics Inc. stock perform well during market downturnsTremendous wealth creation - Jammu Links News
When is Aptevo Therapeutics Inc. stock expected to show significant growthInvest smarter with actionable market insights - Jammu Links News
What drives Aptevo Therapeutics Inc. stock priceUnlock daily market insights for better trades - Jammu Links News
What are the latest earnings results for Aptevo Therapeutics Inc.Build a portfolio for long-term financial success - Jammu Links News
Should I hold or sell Aptevo Therapeutics Inc. stock in 2025Unlock your trading potential today - Jammu Links News
What are Aptevo Therapeutics Inc. company’s key revenue driversBuild wealth faster with consistent growth stocks - Jammu Links News
What are the technical indicators suggesting about Aptevo Therapeutics Inc.Wealth Building Trend Scanner For Smart Trading - Jammu Links News
Aptevo Therapeutics Inc. Shows Support at Fibonacci LevelFree Elite Traders Group - beatles.ru
What is Aptevo Therapeutics Inc. company’s growth strategyInvest smarter with advanced market data - Jammu Links News
Is Aptevo Therapeutics Inc. a Top Dividend Stock to Watch in 2025Top Gaining Low Risk Assets - metal.it
Is Aptevo Therapeutics Inc. a growth stock or a value stockTransform your portfolio with high-yield stocks - jammulinksnews.com
Aptevo Therapeutics' Equity Offering: Strategic Opportunity or Investor Warning? - AInvest
Aptevo Therapeutics Inc. Stock Analysis and ForecastMarket-crushing profits - PrintWeekIndia
Aptevo Therapeutics Files Registration Statement for Share Resale by Stockholder - 富途牛牛
Aptevo Therapeutics' Share Resale and Its Implications for Liquidity and Shareholder Value - AInvest
Aptevo Therapeutics files to sell 8.25M shares of common stock for holders - MSN
Aptevo Therapeutics' $8M Share and Warrant Offering: Balancing Dilution with Strategic Clinical Development - AInvest
Aptevo Therapeutics (APVO) Schedules Offering of 8.25 Million Shares - GuruFocus
What analysts say about Aptevo Therapeutics Inc. stockHigh-profit stock alerts - PrintWeekIndia
Aptevo Therapeutics Inc Stock (APVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):